Recce Pharmaceuticals’ R327 Gel Shows Promising Trial Results
Company Announcements

Recce Pharmaceuticals’ R327 Gel Shows Promising Trial Results

Recce Pharmaceuticals Ltd. (AU:RCE) has released an update.

Recce Pharmaceuticals has announced promising interim results from its Phase II trial for the R327 Gel, a new anti-infective treatment for bacterial skin infections, including diabetic foot infections. The trial has shown that the gel is safe and effective, with all patients achieving complete cure or improvement, and no serious adverse events reported. This positive feedback supports Recce’s potential to address unmet medical needs in treating severe bacterial infections.

For further insights into AU:RCE stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Australian Auto-Generated NewsdeskRecce Pharmaceuticals Advances in Skin Infection Trial
TipRanks Australian Auto-Generated NewsdeskRecce Pharmaceuticals Holds Key Shareholder Meeting
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App